dokumendiregister.ee
OtsingAsutusedMCP
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Pöördumine

Sotsiaalministeerium · 30. november 2020
Viit
1.4-2/3441-1
Registreeritud
30. november 2020
Dokumendi liik
Sissetulev kiri
Adressaat
World Health Organization
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2020
Vastutaja
Hanna Alajõe (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Euroopa Liidu ja väliskoostöö osakond)

Failid

  • 📎C.L.53.2020 Covax Facility.pdf137 KB
  • 📎E-kiri.pdf67 KB

Sisu (failidest)

Saatja: <[email protected]> Saadetud: 27.11.2020 19:28 Koopia: <[email protected]> Teema: C.L.53.2020 (Covax Facility) Dear Member States of the World Health Organization,Please find attached, in the six official languages, C.L.53.2020 regarding the product liability and product labelling issues that will impact access to COVID- 19 vaccines distributed through the COVAX Facility.Should you have questions regarding C.L.53.2020 please send an email to .Best regards,Department of Governing BodiesWorld Health Organization 20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Ref.: C.L.53.2020 Product liability and product labelling issues that will impact access to COVID-19 vaccines distributed through the COVAX Facility The Director-General of the World Health Organization (WHO) presents his compliments to WHO Member States and has the honour to refer to the COVAX Facility, the Global Vaccine Facility of the Access to COVID-19 Tools (ACT) Accelerator, that WHO is co-leading with Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI). One of the overarching objectives of the COVAX Facility is to facilitate the equitable access to COVID-19 vaccines distributed under COVAX. Given the unprecedented nature and scale of the COVID-19 pandemic, as well as the speed at which COVID-19 vaccines are being developed and are expected to be deployed on a global basis, the Director-General would like to bring Member States’ attention to two important issues that will impact countries’ access to such vaccines. These issues are: (i) adequately addressing product liability risks associated with COVID-19 vaccines distributed under COVAX; and (ii) exercising necessary product labelling exemptions, as labelling compliant with national requirements may not be available from the outset of deployment. The Director-General is inviting Member States to ensure that the following actions in the areas of product liability risks and product labelling are promptly taken to avoid any limits or delays in accessing COVID-19 vaccines distributed under COVAX. Addressing product liability risks (including through implementing legislation, if needed) The COVAX Facility is working to find a practical solution to the issue of liability in respect of COVID-19 vaccines distributed under COVAX, as manufacturers have expressed reluctance to deliver COVID-19 vaccines to countries participating in COVAX unless product liability risks are adequately addressed. The solution aims to be equitable to all stakeholders and mitigate anticipated financial risks to the Advance Market Commitment (AMC)-eligible economies, as much as reasonably possible. The three main pillars of the solution are: (i) a requirement that all countries participating in COVAX enter into indemnification agreements with vaccine manufacturers; and, for AMC-eligible economies only; (ii) the issuance of indemnity backstopping guarantees by a third party; and (iii) the establishment of a compensation mechanism to compensate individuals suffering serious adverse events associated with COVID-19 vaccines distributed under COVAX. Information on the proposed liability solution can be found at: https://www.gavi.org/sites/default/files/covid/covax/BRIEFING- NOTE-Indemnification-and-Compensation-COVAX-AMC-Countries.pdf. Page 2 C.L.53.2020 The Director-General hereby invites Member States to take urgent actions to: 1. Determine whether implementing legislation needs to be enacted within their country to enable governments to indemnify manufacturers and other relevant stakeholders and/or to enable persons within their country to accept payments under the proposed COVAX compensation mechanism in full and final settlement of any claims. 2. If any such legislation is needed based on the above, draft and enact all necessary implementing legislation as soon as possible before the supply of COVID-19 vaccines under COVAX commences. COVAX is seeking to obtain dedicated advisory support to assist AMC-eligible economies, should they so desire, in respect of the actions above. Product labelling COVID-19 vaccines are being manufactured ahead of the decisions on countries in which they may ultimately be deployed. This advanced manufacturing is necessary to ensure the rapid deployment of the vaccines once regulatory approval and policy decisions have been made to deploy the vaccines. There is, however, no universal agreement for the format and content of vaccine vial and packaging labels. Multiple, country-specific national requirements are not compatible with timely access to these potentially lifesaving vaccines. WHO has developed models for vials and secondary packaging to unify the labelling requirements for vaccines that will be supplied through the COVAX Facility. The model labels, relevant for vaccines supplied through UN procurement agencies, are available at: https://www.who.int/teams/regulation- prequalification/eul/covid-19/covid-19-model-packaging. Similarly WHO has developed working positions to leverage the use of 2D bar code technology on secondary packaging in the context of traceability systems, and the use of QR code technologies on primary and/or secondary packaging for supplemental electronic access to label and leaflet information (considered optional, and not in lieu of related statutory requirements). The working positions can be accessed at: https://www.who.int/publications/m/item/bar-codes-qr-codes-and-vaccine-vial-monitors-in-the- context-of-covid-19-vaccines. Member States are invited to take the following urgent actions: 1. Determine under what provisions the national medicines regulatory authority can issue an exemption for certain labelling requirements for COVID-19 vaccines distributed under COVAX. Page 3 C.L.53.2020 2. Ensure that the national medicines regulatory authority can: (i) authorize COVID-19 vaccines distributed by the COVAX Facility that are labelled in compliance with the WHO models; (ii) authorize the translated label information in local languages (i.e. other than the six UN official languages) for printing and distribution. The Director-General of the World Health Organization takes the opportunity to renew to Member States the assurance of his highest consideration. GENEVA, 27 November 2020
Allikas: Sotsiaalministeerium dokumendiregister →